• F. Markus LewekeEmail author
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 1)


Since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the potential role of this system in schizophrenia. On the basis of earlier epidemiological studies and results from animal models, endocannabinoids and their relation to symptoms are considered in clinical studies as well as in post-mortem analyses of cannabinoid CB1 receptor densities. A possible neurobiological mechanism for the deleterious influence of cannabis use in schizophrenia is discussed, involving the disruption of endogenous cannabinoid signalling and function.


Schizophrenia Endocannabinoids Δ9-THC Animal modes CSF 



Anterior cingulate cortex


Cerebrospinal fluid


Posterior cingulate cortex



This research was funded by the Stanley Medical Research Institute (01-315 and 03-NV-003 to FML) and the Koeln Fortune Program (108-2000 to FML). I gratefully acknowledge the contributions of Drs. L. Kranaster, D. Koethe, C.W. Gerth, C. Hoyer, B.M. Nolden, C. Mauss, D. Schreiber, F. Pahlisch, and C. Jöpen to this research.


  1. Andreasson S, Allebeck P, Engstrom A et al. (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483–1486PubMedCrossRefGoogle Scholar
  2. Andreasson S, Allebeck P, Rydberg U (1989) Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiat Scand 79:505–510PubMedCrossRefGoogle Scholar
  3. Arseneault L, Cannon M, Poulton R et al. (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 325:1212–1213CrossRefGoogle Scholar
  4. Arseneault L, Cannon M, Witton J et al. (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117PubMedCrossRefGoogle Scholar
  5. Dean B, Sundram S, Bradbury R et al. (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15PubMedCrossRefGoogle Scholar
  6. D'Souza CD, Perry E, MacDougall L et al. (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558–1572PubMedCrossRefGoogle Scholar
  7. D'Souza DC, Abi-Saab WM, Madonick S et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608PubMedCrossRefGoogle Scholar
  8. Eggan SM, Hashimoto T, Lewis DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65:772–784PubMedCrossRefGoogle Scholar
  9. Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to a dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803–807PubMedCrossRefGoogle Scholar
  10. Giuffrida A, Parsons LH, Kerr TM et al. (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363PubMedCrossRefGoogle Scholar
  11. Giuffrida A, Leweke FM, Gerth CW et al. (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108–2114PubMedCrossRefGoogle Scholar
  12. Gregg L, Barrowclough C, Haddock G (2007) Reasons for increased substance use in psychosis. Clin Psychol Rev 27:494–510PubMedCrossRefGoogle Scholar
  13. Henquet C, Krabbendam L, Spauwen J et al. (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J 330:11–16CrossRefGoogle Scholar
  14. Koethe D, Gerth CW, Neatby MA et al. (2006) Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr Res 88:142–150PubMedCrossRefGoogle Scholar
  15. Koethe D, Llenos IC, Dulay JR et al. (2007) Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 114:1055–1063PubMedCrossRefGoogle Scholar
  16. Kovasznay B, Fleischer J, Tanenberg Karant M et al. (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23:195–201PubMedGoogle Scholar
  17. Leweke FM, Kampmann C, Radwan M et al. (1998) The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology 37:104–111PubMedCrossRefGoogle Scholar
  18. Leweke FM, Giuffrida A, Wurster U et al. (1999a) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665–1669PubMedCrossRefGoogle Scholar
  19. Leweke FM, Schneider U, Thies M et al. (1999b) Effects of synthetic Δ9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 142:230–235PubMedCrossRefGoogle Scholar
  20. Leweke FM, Schneider U, Radwan M et al. (2000) Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 66:175–181PubMedCrossRefGoogle Scholar
  21. Leweke FM, Koethe D, Gerth CW et al. (2005) The endocannabinoid modulator cannabidiol as an antipsychotic. Results from the first controlled clinical trial in acute schizophrenia. Biol Psychiat 57:S135Google Scholar
  22. Leweke FM, Giuffrida A, Koethe D et al. (2007a) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94(1–3):29–36PubMedCrossRefGoogle Scholar
  23. Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279PubMedGoogle Scholar
  24. Meltzer HY, Arvanitis L, Bauer D et al. (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975–984PubMedCrossRefGoogle Scholar
  25. Moreau de Tours J-J (1845) Du hachisch et de l'aliénation mentale, Études psychologiques. Paris, Fortin et MassonGoogle Scholar
  26. Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556–560PubMedCrossRefGoogle Scholar
  27. Poncelet M, Barnouin M-C, Breliere J-C et al. (1999) Blockade of cannabinoid (CB1) receptors by SR 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology 144:144–150PubMedCrossRefGoogle Scholar
  28. Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13:253–263PubMedCrossRefGoogle Scholar
  29. Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760–1769PubMedCrossRefGoogle Scholar
  30. Schneider M, Koch M (2005) Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30:944–957PubMedCrossRefGoogle Scholar
  31. Schneider M, Drews E, Koch M (2005) Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55, 212-2. Behav Pharmacol 16:447–454PubMedCrossRefGoogle Scholar
  32. Sundram S (2006) Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol 21:245–254PubMedCrossRefGoogle Scholar
  33. van Os J, Bak M, Hanssen M et al. (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:319–327PubMedCrossRefGoogle Scholar
  34. Veen ND, Selten JP, van der Tweel I et al. (2004) Cannabis use and age at onset of schizophrenia. Am J Psychiatry 161:501–506PubMedCrossRefGoogle Scholar
  35. Zammit S, Allebeck P, Andreasson S et al. (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br Med J 325:1199–1203CrossRefGoogle Scholar
  36. Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355–360PubMedCrossRefGoogle Scholar
  37. Zuardi AW, Rodrigues JA, Cunha JM (1991) Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 104:260–264PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  1. 1.Department of Psychiatry and PsychotherapyCentral Institute of Mental HealthMannheimGermany

Personalised recommendations